<DOC>
	<DOCNO>NCT01994824</DOCNO>
	<brief_summary>Graft-vs-host disease ( GVHD ) cause substantial mortality , morbidity poor quality life blood marrow transplantation ( BMT ) . In Alberta , use antithymocyte globulin ( ATG , give day -2 , -1 0 ) addition methotrexate cyclosporine GVHD prophylaxis . In spite , ~40 % patient develop significant GVHD ( grade 2-4 acute GVHD chronic GVHD need systemic immunosuppressive therapy ) . ATG dose typically use ( 4.5 mg/kg ) relatively non-toxic . At high dos , ATG could increase likelihood posttransplant infection relapse . Thus extra dose ATG ( top routine 4.5 mg/kg ) might justify patient high risk develop significant GVHD . In experience , low serum level interleukin-15 ( IL15 ) high serum level interleukin-2 receptor alpha ( IL2Ra ) day 7 predict development significant GVHD . Here test whether , compare historical/concurrent control , extra dose ATG ( 3 mg/kg day 8 ) give patient low IL15 high IL2Ra day 7 reduces incidence significant GVHD , improve survival free relapse GVHD , quality life .</brief_summary>
	<brief_title>Preemptive Therapy GVHD</brief_title>
	<detailed_description>Blood IL15 IL2Ra determination drawn morning day 7 ( 10 ml red top tube ) . IL15 IL2Ra level measure Storek/Khan Lab enzyme-linked immunosorbent assay ( ELISA ) describe ( Pratt LM et al : BMT 2013 ) . Storek/Khan Lab staff report IL15 IL2Ra level Bone Marrow Transplant ward ( Unit 57 , Foothills Medical Centre ) later morning day 8 . If IL15 level &lt; 31 ng/L IL2Ra level &gt; 4500 ng/L , physician caring patient ward order Thymoglobulin , 3 mg/kg intravenously , infuse 4-8 hour day 8 . The dose base actual body weight , round near vial ( Thymoglobulin supply 25 mg vial ) except round would result &gt; 5 % difference calculate dose . Unit 57 standard practice follow infusion ATG ( see Standard Operation Procedure BMTS40153 [ `` ATG Administration '' ] ) . Premedication ATG include methylprednisolone 40 mg IVPB , acetaminophen 1000 mg PO diphenhydramine 50 mg IVPB . Acetaminophen 1000 mg PO diphenhydramine 50 mg IVPB repeat 4-6 hour PRN flu-like symptoms/fever/chills . Meperidine 25-50 mg IVPB every 4 hour give PRN rigor . EVALUATIONS For endpoint incidence significant GVHD , patient follow per standard practice Alberta Blood Marrow Transplant Program development acute chronic GVHD ( www.albertahealthservices.ca/hp/if-hp-cancer-guide-bmt-manual.pdf ) . Per standard practice , acute GVHD grade accord Consensus criterion ( Przepiorka D : BMT 1995 ) chronic GVHD diagnose grade accord NIH criterion ( Filipovich AH : BBMT 2005 ) . Significant GVHD define grade 2-4 acute GVHD chronic GVHD need systemic immunosuppressive therapy . For endpoint survival free significant GVHD relapse , relapse define standard criterion ( eg , &gt; 5 % marrow blast morphology case acute leukemia ) . For endpoint quality life 2 year ( 21-27 month ) posttransplant , Short Form 36 use .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>1 . First allogeneic hematopoietic cell transplantation ( second transplant rare , typically perform relapse leukemia , case likelihood relapse high , theoretical risk increase likelihood ATG ) . 2 . Conditioning include ATG 4.5 mg/kg ( predictive value IL15 IL2Ra level determine patient whose condition include 4.5 mg/kg ATG ) . 3 . Age &gt; 17 ( predictive value IL15 IL2Ra level study child ) . 1 . Nonmyeloablative conditioning ( possible risk ATG increase relapse ) . 2 . Active viral infection ( risk worsen viral infection ATG ) . 3 . Neutropenic fever hypotension . In case , ATG give day 9 ( instead day 8 ) patient long hypotension . 4 . Hypoxemia . In case , ATG give day 9 ( instead day 8 ) patient longer hypoxemia . 5 . History anaphylactic reaction Thymoglobulin another rabbit blood protein .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>